Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis

Herpes Simplex Virus 1 (HSV1) is amongst the most clinically advanced oncolytic virus platforms. However, efficient and sustained viral replication within tumours is limiting. Rapamycin can stimulate HSV1 replication in cancer cells, but active-site dual mTORC1 and mTORC2 (mammalian target of rapamycin complex 1 and 2) inhibitors (asTORi) were shown to suppress the virus in normal cells. Surprisingly, using the infected cell protein 0 (ICP0)-deleted HSV1 (HSV1-dICP0), we found that asTORi markedly augment infection in cancer cells and a mouse mammary cancer xenograft. Mechanistically, asTORi repressed mRNA translation in normal cells, resulting in defective antiviral response but also inhibition of HSV1-dICP0 replication. asTORi also reduced antiviral response in cancer cells, however in contrast to normal cells, transformed cells and cells transduced to elevate the expression of eukaryotic initiation factor 4E (eIF4E) or to silence the repressors eIF4E binding proteins (4E-BPs), selectively maintained HSV1-dICP0 protein synthesis during asTORi treatment, ultimately supporting increased viral replication. Our data show that altered eIF4E/4E-BPs expression can act to promote HSV1-dICP0 infection under prolonged mTOR inhibition. Thus, pharmacoviral combination of asTORi and HSV1 can target cancer cells displaying dysregulated eIF4E/4E-BPs axis.

[1]  Michael E. Lassman,et al.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy , 2017, Cell.

[2]  T. Alain,et al.  Battling for Ribosomes: Translational Control at the Forefront of the Antiviral Response. , 2018, Journal of molecular biology.

[3]  S. Russell,et al.  Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines. , 2018, Cancer cell.

[4]  J. Bromberg,et al.  Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming , 2017, Genes & development.

[5]  Michael E. Lassman,et al.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy , 2017, Cell.

[6]  R. Kratzke,et al.  Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma , 2017, Oncotarget.

[7]  C. Thirukkumaran,et al.  Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy , 2017, Front. Oncol..

[8]  T. Cripe,et al.  Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients , 2017, Clinical Cancer Research.

[9]  D. Sabatini,et al.  mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.

[10]  Michael C. Brown,et al.  MNK Controls mTORC1:Substrate Association through Regulation of TELO2 Binding with mTORC1. , 2017, Cell reports.

[11]  W. Chan,et al.  Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas , 2017, Haematologica.

[12]  G. Gores,et al.  Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells , 2016, Oncotarget.

[13]  R. Nadon,et al.  Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3 , 2016, Nature Communications.

[14]  J. Moffat,et al.  Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells , 2016, Oncogene.

[15]  M. Diamond,et al.  S6K-STING interaction regulates cytosolic DNA–mediated activation of the transcription factor IRF3 , 2016, Nature Immunology.

[16]  J. Pelletier,et al.  nanoCAGE reveals 5′ UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs , 2016, Genome research.

[17]  H. Wakimoto,et al.  Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma. , 2016, American journal of cancer research.

[18]  Asher Mullard.  FDA approves anticoagulant antidote , 2015, Nature Reviews Drug Discovery.

[19]  Asher Mullard.  Regulators approve the first cancer-killing virus , 2015, Nature Reviews Drug Discovery.

[20]  H. Kaufman,et al.  Oncolytic viruses: a new class of immunotherapy drugs , 2015, Nature Reviews Drug Discovery.

[21]  Eugenia G. Giannopoulou,et al.  Interferon-γ regulates cellular metabolism and mRNA translation to potentiate macrophage activation , 2015, Nature Immunology.

[22]  Troy Guthrie,et al.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  N. Sonenberg,et al.  Targeting the translation machinery in cancer , 2015, Nature Reviews Drug Discovery.

[24]  T. Alain,et al.  Deficiency in Either 4E-BP1 or 4E-BP2 Augments Innate Antiviral Immune Responses , 2014, PloS one.

[25]  T. Alain,et al.  The ever-evolving role of mTOR in translation. , 2014, Seminars in cell & developmental biology.

[26]  T. Alain,et al.  Polysome Fractionation and Analysis of Mammalian Translatomes on a Genome-wide Scale , 2014, Journal of visualized experiments : JoVE.

[27]  W. Halford,et al.  Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  N. Sonenberg,et al.  mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. , 2013, Cell metabolism.

[29]  S. Workenhe,et al.  Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy , 2013, Cancer Immunology Research.

[30]  M. Wilck,et al.  Herpes Simplex Virus in Solid Organ Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  N. Sonenberg,et al.  eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. , 2012, Cancer Research.

[32]  I. Mohr,et al.  Control of viral latency in neurons by axonal mTOR signaling and the 4E-BP translation repressor. , 2012, Genes & development.

[33]  N. Sonenberg,et al.  Translational homeostasis via the mRNA cap-binding protein, eIF4E. , 2012, Molecular cell.

[34]  B. Su,et al.  Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses , 2012, Proceedings of the National Academy of Sciences.

[35]  M. Hall,et al.  Rapamycin passes the torch: a new generation of mTOR inhibitors , 2011, Nature Reviews Drug Discovery.

[36]  Xiaoliu Zhang,et al.  Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication , 2011, International journal of cancer.

[37]  K. Shokat,et al.  Constitutive mTORC1 activation by a herpesvirus Akt surrogate stimulates mRNA translation and viral replication. , 2010, Genes & development.

[38]  N. Sonenberg,et al.  mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs , 2010, Science.

[39]  Marie Nguyen,et al.  A practical approach to RT-qPCR-Publishing data that conform to the MIQE guidelines. , 2010, Methods.

[40]  T. Shenk,et al.  Rapamycin-Resistant mTORC1 Kinase Activity Is Required for Herpesvirus Replication , 2010, Journal of Virology.

[41]  R. Jackson,et al.  The mechanism of eukaryotic translation initiation and principles of its regulation , 2010, Nature Reviews Molecular Cell Biology.

[42]  T. Alain,et al.  Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. , 2010, Cancer research.

[43]  B. Pulendran,et al.  Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production , 2010, Proceedings of the National Academy of Sciences.

[44]  K. Shokat,et al.  Constitutive mTORC 1 activation by a herpesvirus Akt surrogate stimulates mRNA translation and viral replication , 2010 .

[45]  C. Nutt,et al.  Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide , 2009, Clinical Cancer Research.

[46]  V. Beneš,et al.  The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. , 2009, Clinical chemistry.

[47]  L. Platanias,et al.  Interferon-Dependent Engagement of Eukaryotic Initiation Factor 4B via S6 Kinase (S6K)- and Ribosomal Protein S6K-Mediated Signals , 2009, Molecular and Cellular Biology.

[48]  Robbie Loewith,et al.  Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 , 2009, PLoS biology.

[49]  B. Pulendran,et al.  Toll-like receptor–mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway , 2008, Nature Immunology.

[50]  L. Platanias,et al.  Akt and mRNA translation by interferons , 2008, Cell cycle.

[51]  N. Sonenberg,et al.  Translational control of the innate immune response through IRF-7 , 2008, Nature.

[52]  G. McFadden,et al.  Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[53]  T. Alain,et al.  Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. , 2007, Cancer research.

[54]  J. Baselga,et al.  4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. , 2007, Cancer research.

[55]  D. Huntsman,et al.  Elevated Expression of DecR1 Impairs ErbB2/Neu-Induced Mammary Tumor Development , 2007, Molecular and Cellular Biology.

[56]  N. Sonenberg,et al.  Regulatory Effects of Mammalian Target of Rapamycin-activated Pathways in Type I and II Interferon Signaling* , 2007, Journal of Biological Chemistry.

[57]  K. Mossman,et al.  The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  S K Burley,et al.  Hierarchical phosphorylation of the translation inhibitor 4E-BP1. , 2001, Genes & development.

[59]  E. Feldman,et al.  IGF-I receptor activation and BCL-2 overexpression prevent early apoptotic events in human neuroblastoma , 2000, Cell Death and Differentiation.

[60]  N. Sonenberg,et al.  Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap , 1990, Nature.

[61]  R. Ross,et al.  Transdifferentiation of human neuroblastoma cells results in coordinate loss of neuronal and malignant properties. , 1988, Progress in clinical and biological research.

[62]  B. Pulendran,et al.  Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI ( 3 ) K-mTOR-p 70 S 6 K pathway , 2022 .